Pharmala Biotech Holdings (XCNQ:MDMA) NonCurrent Deferred Liabilities : C$0.00 Mil (As of Feb. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Pharmala Biotech Holdings's non-current deferred liabilities for the quarter that ended in Feb. 2024 was C$0.00 Mil.

Pharmala Biotech Holdings NonCurrent Deferred Liabilities Historical Data

The historical data trend for Pharmala Biotech Holdings's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings NonCurrent Deferred Liabilities Chart

Pharmala Biotech Holdings Annual Data

Trend

Aug21

Aug22

Aug23

Aug24

NonCurrent Deferred Liabilities

Pharmala Biotech Holdings Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	Aug24
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial								-	-	-	-	-

Pharmala Biotech Holdings NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

MDXXF:USA

Address

82 Richmond Street East, Toranto, ON, CAN, M5C 1P1

Website

https://www.pharmala.ca

Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations.

Executives

Perry Tsergas	Director
Shane H.d. Morris	Director, Senior Officer
Nicholas Kadysh	Director, Senior Officer
Fraser Macdonald	Director

Pharmala Biotech Holdings Headlines

No Headlines